Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1989 Aug;33(8):1160–1166. doi: 10.1128/aac.33.8.1160

In vitro activity of CP-65,207, a new penem antimicrobial agent, in comparison with those of other agents.

T Gootz 1, J Retsema 1, A Girard 1, E Hamanaka 1, M Anderson 1, S Sokolowski 1
PMCID: PMC172617  PMID: 2679370

Abstract

CP-65,207 is a new parenteral penem antibiotic with a broad spectrum that includes gram-positive, gram-negative, and anaerobic microorganisms, with MICs for 90% (MIC90s) of the majority of 1,101 clinical pathogens tested being less than or equal to 1 microgram/ml. The compound was from 10- to 100-fold more active than cefoxitin and broad-spectrum cephalosporins against gram-positive bacteria and anaerobes. CP-65,207 was less active than imipenem for staphylococci, group A streptococci, and Enterococcus faecalis. Against members of the family Enterobacteriaceae, CP-65,207 was in general 100-fold more active than cefoxitin, 5- to 10-fold more active than broad-spectrum cephalosporins, and 2-fold more active than imipenem. Fresh clinical isolates that were resistant to broad-spectrum cephalosporins were highly susceptible to CP-65,207 and imipenem (MIC90, 1 microgram/ml). Isolates of Enterococcus faecalis, Serratia marcescens, and anaerobic Peptococcus spp. had MIC90s of 8, 2, and 3.12 micrograms/ml, respectively. CP-65,207 was not very active against methicillin-resistant staphylococci or Pseudomonas aeruginosa. Killing kinetics showed that against some strains CP-65,207 is rapidly bactericidal at concentrations well below those required to achieve a similar degree of killing with cefotaxime, ceftazidime, and ceftriaxone. CP-65,207 was only slightly susceptible to hydrolysis by type I cephalosporinases and TEM-1, SHV-1, and PSE-2 plasmid-encoded enzymes. It had the highest affinity for penicillin-binding proteins 2, 1A, 1B, and 3 in cell-free preparations of Escherichia coli W-7.

Full text

PDF
1160

Images in this article

1165Image
on p.1165

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Beckwith D. G., Jahre J. A. Role of a cefoxitin-inducible beta-lactamase in a case of breakthrough bacteremia. J Clin Microbiol. 1980 Oct;12(4):517–520. doi: 10.1128/jcm.12.4.517-520.1980. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Brown R. M., Wise R., Andrews J. M. Sch 29482--a novel penem antibiotic: an in-vitro comparison of its activity with other beta-lactams. J Antimicrob Chemother. 1982 Feb;9 (Suppl 100):17–23. doi: 10.1093/jac/9.suppl_c.17. [DOI] [PubMed] [Google Scholar]
  3. Gootz T. D., Sanders C. C., Goering R. V. Resistance to cefamandole: derepression of beta-lactamases by cefoxitin and mutation in Enterobacter cloacae. J Infect Dis. 1982 Jul;146(1):34–42. doi: 10.1093/infdis/146.1.34. [DOI] [PubMed] [Google Scholar]
  4. Gootz T. D., Sanders C. C., Sanders W. E., Jr In vitro activity of furazlocillin (Bay k 4999) compared with those of mezlocillin, piperacillin, and standard beta-lactam antibiotics. Antimicrob Agents Chemother. 1979 Jun;15(6):783–791. doi: 10.1128/aac.15.6.783. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Kahan F. M., Kropp H., Sundelof J. G., Birnbaum J. Thienamycin: development of imipenen-cilastatin. J Antimicrob Chemother. 1983 Dec;12 (Suppl 500):1–35. doi: 10.1093/jac/12.suppl_d.1. [DOI] [PubMed] [Google Scholar]
  6. LOWRY O. H., ROSEBROUGH N. J., FARR A. L., RANDALL R. J. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951 Nov;193(1):265–275. [PubMed] [Google Scholar]
  7. Neu H. C., Chin N. X., Labthavikul P. The in-vitro activity of a novel penem FCE 22101 compared to other beta-lactam antibiotics. J Antimicrob Chemother. 1985 Sep;16(3):305–313. doi: 10.1093/jac/16.3.305. [DOI] [PubMed] [Google Scholar]
  8. Neu H. C., Chin N. X., Neu N. M. In vitro activity and beta-lactamase stability of a new penem, CGP 31608. Antimicrob Agents Chemother. 1987 Apr;31(4):558–569. doi: 10.1128/aac.31.4.558. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Neu H. C., Labthavikul P. Antibacterial activity of an oral penem, Sch 29482. J Antimicrob Chemother. 1982 Feb;9 (Suppl 100):49–57. doi: 10.1093/jac/9.suppl_c.49. [DOI] [PubMed] [Google Scholar]
  10. Norrby S. R., Jonsson M. Comparative in vitro antibacterial activity of Sch 34343, a novel penem antibiotic. Antimicrob Agents Chemother. 1985 Jan;27(1):128–131. doi: 10.1128/aac.27.1.128. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Sanders C. C., Moellering R. C., Jr, Martin R. R., Perkins R. L., Strike D. G., Gootz T. D., Sanders W. E., Jr Resistance to cefamandole: a collaborative study of emerging clinical problems. J Infect Dis. 1982 Jan;145(1):118–125. doi: 10.1093/infdis/145.1.118. [DOI] [PubMed] [Google Scholar]
  12. Sanders C. C., Sanders W. E., Jr Emergence of resistance during therapy with the newer beta-lactam antibiotics: role of inducible beta-lactamases and implications for the future. Rev Infect Dis. 1983 Jul-Aug;5(4):639–648. doi: 10.1093/clinids/5.4.639. [DOI] [PubMed] [Google Scholar]
  13. Seibert G., Isert D., Klesel N., Limbert M., Pries A., Schrinner E., Cooke M., Walmsley J., Bentley P. H. HRE 664, a new parenteral penem. I. Antibacterial activity in vitro. J Antibiot (Tokyo) 1987 May;40(5):660–667. doi: 10.7164/antibiotics.40.660. [DOI] [PubMed] [Google Scholar]
  14. Spratt B. G. Properties of the penicillin-binding proteins of Escherichia coli K12,. Eur J Biochem. 1977 Jan;72(2):341–352. doi: 10.1111/j.1432-1033.1977.tb11258.x. [DOI] [PubMed] [Google Scholar]
  15. Then R. L., Angehrn P. Trapping of nonhydrolyzable cephalosporins by cephalosporinases in Enterobacter cloacae and Pseudomonas aeruginosa as a possible resistance mechanism. Antimicrob Agents Chemother. 1982 May;21(5):711–717. doi: 10.1128/aac.21.5.711. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Van der Auwera P., Ernst F., Grenier P., Glupczynski Y., Husson M., Klastersky J. In-vitro activity of two new carbapenems FCE 22101 and CGP 31608 in comparison with imipenem. J Antimicrob Chemother. 1987 Aug;20(2):179–189. doi: 10.1093/jac/20.2.179. [DOI] [PubMed] [Google Scholar]
  17. Yoshimura F., Nikaido H. Diffusion of beta-lactam antibiotics through the porin channels of Escherichia coli K-12. Antimicrob Agents Chemother. 1985 Jan;27(1):84–92. doi: 10.1128/aac.27.1.84. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Zak O., Lang M., Cozens R., Konopka E. A., Mett H., Schneider P., Tosch W., Scartazzini R. Penems: in vitro and in vivo experiments. J Clin Pharmacol. 1988 Feb;28(2):128–135. doi: 10.1002/j.1552-4604.1988.tb05736.x. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES